Drug resistance mechanisms in acute leukemia

Current Opinion in Oncology

Volumn 13, Issue 1, 2001, Pages 21-26

  Chauncey, Thomas R ^a  

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; AMDREY; CYCLOSPORIN; CYCLOSPORIN DERIVATIVE; GLYCOPROTEIN P; LUNG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN; PROTEIN BCL 2; VALSPODAR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; CANCER SURVIVAL; CHEMOSENSITIVITY; DISEASE MARKER; DRUG SENSITIVITY; GENE OVEREXPRESSION; MULTIDRUG RESISTANCE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEQUENCE HOMOLOGY; TREATMENT OUTCOME;

ATP-BINDING CASSETTE TRANSPORTERS; DRUG INTERACTIONS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; PHENOTYPE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0035166135     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200101000-00005     Document Type: Review

References (65)

1. The immunophenotype of 177 adults with acute myeloid leukemia: Proposol of a prognostic score
2. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial
3. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype
4. Intensive postremission chemotherapy in adults with acute myeloid leukemia
5. Revised classification of acute myeloid leukemia
6. Management of acute myeloid leukemia in elderly patients
7. Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia: Cancer and leukemia group B study 8364
8. Multidrug resistance in haematological malignancies
9. The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia
10. In vitro effect of multidrug resistance modifiers on idarubicinol efflux in blasts of acute myeloid leukemia
11. Effect of PSC 833 on the cytotoxicity of idarubicin and idarubicinol in multidrug-resistant K562 cells
12. An inventory of the human ABC proteins
13. Molecular aspects of hepatobiliary transport
14. Atypical multidrug resistance: Breast cancer resistance protein messenger RNA expression in mitoxantroneselected cell lines, J Natl Cancer Inst
15. A multidrug resistance transporter from human MCF-7 breast cancer cells
16. Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubucin and with in vivo resistance in adult acute myeloid Leukemia
17. Multidrug resistance-associated protein in acute myeloid leukemia: No impact on treatment outcome
18. Lung resistance-related protein: Determining its role in multidrug resistance
19. Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia
20. Vaults are up-regulated in multidrug-resistant cancer cell lines
21. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia
22. Evidence for a critical role of DNA topoisomerase II alpha in drug sensitivity revealed by inducible antisense RNA in a human leukaemia cell line
23. Topoisomerase II activities in AML blasts and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxines
24. Resistance to the chemosensitizer verapamil in a multi-drug-resistant (MDR) human multiple myeloma cell line
25. Verapamil suppresses the emergence of P-glycoprotein-mediated multi-drug resistance
26. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdrl gene activation by the cyclosporin PSC 833
27. Bcl-2, bax and bcl-xL expression in human sensitive and resistant cell lines
28. Measurement of spontaneous and therapeutic agent-induced apoptosis with BCL-2 protein expression in acute myeloid leukemia
29. Characterization of newly established human myeloid leukemia cell line (KF-19) and its drug resistant sublines
30. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: Consensus recommendations
31. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia
32. Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy
33. Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray
34. Lung resistance protein (LRP) gene expression in adult acute myeloid leukemia: A critical evaluation by three techniques
35. P-glycoprotein (POP), lung resistance-related protein (LRP) and multidrug resistance-associated protein (MRP) expression in acute promyelocytic leukaemia
36. Influence of SDZ-PSO833 on daunorubicin intracellular accumulation in bone marrow specimens from patients with acute myeloid leukemia
37. Novel mechanisms of drug resistance in leukemia
38. Drug resistance factors in acute myeloid leukemia: A comparative analysis
39. Functional MDR1 expression in adult acute lymphoblastic leukemia (ALL)
40. Expression of the multidrug resistance P glycoprotein in newly diagnosed adult acute lymphoblastic leukemia: Absence of correlation with response to treatment
41. The expression of the multidrug resistance related glycoprotein in adult acute lymphoblastic leukemia
42. Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia?
43. Topoisomerase II levels and DNA fragmentation in leukemia blasts treated with topotecan followed by etoposide + mitoxantrone (T-EM) in a timed sequential chemotherapy regimen
44. Topoisomerase II and the response to antileukemic therapy
45. Leukaemia cell drug resistance and prognostic factors in AML
46. Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia
47. Expression of breast cancer resistance protein in blast cells from patients with acute leukemia
48. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia
49. Benefit of cyclosporine (CsA) modulation of anthracycline resistance in high-risk AML: A Southwest Oncology Group (SWOG) study
50. A randomized phase III study of cyclosporine (CSA) modulation of anthracycline resistance in CML-blast phase: Southwest Oneology Group (SWOG) Study 9032
51. Comparison of two chemotherapy regimens, with or without cyclosporine A, in relapsed/refractory acute myeloid leukaemia: Results of the U.K. Medical Research Council AML-R Trial
52. Mitoxantrone, etoposide and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: An Eastern Cooperative Oncology Group pilot study
53. Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia
54. P-glycoprotein inhibitor valspodar (PSO 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia
55. A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: A Southwest Oncology Group Study (9617)
56. Parallel phase I studies of daunomycin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myelogenous leukemia: Results of cancer and leukemia group B study 9420
57. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC833 (valspodar)
58. Phase III study of PSC-833 modulation of multidrug resistance (MDR) in previously untreated acute myeloid leukemia (AML) patients (PTS) ≥ 60 years (CALGB 9720)
59. Treatment of refractory/relapsed AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSG-MEC) vs MEC: Randomized phase III trial (E2995)
60. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979
61. Hypomethylation status of CpG sites at the promoter region and overexpression of the human MDR1 gene in acute myeloid leukemias
62. P-glycoprotein and multidrug resistance-associated protein, but not lung resistance protein, lower the intracellular daunorubicin accumulation in acute myeloid leukaemic cells
63. Altered multidrug resistance phenotype caused by anthracycline analogues and cytosine arabinoside in myeloid leukemia
64. Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin
65. Parallel phase I trials of multi-drug resistance (MDR) modulation with PSC-833 (PSC) in untreated patients with acute myeloid leukemia (AML) < 60 years old: Preliminary results of CALGB 9621